Skip to main content

Table 1 Current Combination Immunotherapy Trials Including HNSCC Patients

From: Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations

Targets Treatments Phase Clinical Trial ID Patient Eligibility Status
Costimulatory/Checkpoint Combinations
 CD137 (4-1BB)
 PD-L1
PF-05082566 + Avelumab Ib/II NCT02554812 Advanced/metastatic solid tumors Recruiting
 CD137 (4-1BB)
 PD-1
PF-05082566 + Pembrolizumab I NCT02179918 Advanced/metastatic solid tumors Recruiting
 OX40
 PD-L1
MEDI6383 +/−Durvalumab I NCT02221960 Recurrent or metastatic solid tumors Recruiting
 OX40
 CTLA-4
 PD-L1
MEDI6469 Alone, + Tremelimumab, or + Durvalumab Ib/II NCT02205333 Advanced solid tumors Ongoing, not recruiting
 CD27
 PD-L1
Varlilumab + Atezolizumab I/II NCT02543645 Advanced cancers including HNSCC Recruiting
 CD27
 PD-1
Varlilumab + Nivolumab I/II NCT02335918 Advanced solid tumors Recruiting
Checkpoint/Checkpoint Combinations
 CTLA-4
 B7-H3
Ipilimumab + MGA271 I NCT02381314 Advanced/metastatic B7-H3+ HNSCC, melanoma, or NSCLC Recruiting
 CTLA-4
 PD-L1
Tremelimumab + Durvalumab III NCT02551159 HNSCC with no prior chemotherapy Recruiting
 CTLA-4
 PD-L1
Tremelimumab + Durvalumab I NCT02262741 Recurrent or metastatic HNSCC Recruiting
 CTLA-4
 PD-L1
Tremelimumab + Durvalumab (monotherapy or combination) II NCT02319044 Recurrent or metastatic HNSCC Ongoing, not recruiting
 CTLA-4
 PD-L1
 Vaccine
Tremelimumab + Durvalumab + PolyICLC I/II NCT02643303 Advanced solid tumors including HPV- HNSCC or HPV+ HNSCC after prior treatment failure Not yet recruiting
 PD-L1
 CTLA-4
Durvalumab +/−Tremelimumab III NCT02369874 Recurrent or metastatic HNSCC Recruiting
 PD-1
 B7-H3
Pembrolizumab + MGA271 I NCT02475213 B7-H3+ advanced HNSCC Recruiting
 PD-L1
 HPV E7
Durvalumab +
ADXS 11–001
I/II NCT02291055 Recurrent or metastatic HPV-associated HNSCC Ongoing, not recruiting
 LAG-3
 PD-1
BMS-986016 +/− Nivolumab I NCT01968109 Advanced solid tumors Recruiting
 LAG-3
 PD-1
LAG525 +/− PDR001 I/II NCT02460224 Advanced solid tumors Recruiting
 TIM-3
 PD-1
MBG453 +/−PDR001 I/II NCT02608268 Advanced solid malignancies Recruiting
Cetuximab Combinations
 CD137 (4-1BB) Urelumab + Cetuximab Ib NCT02110082 Advanced/metastatic HNSCC or CRC Ongoing, not recruiting
 CTLA-4 Iplimumab + Cetuximab + IMRT Ib NCT01860430, NCT01935921 Stage III-IVB HNSCC p16- or intermediate-risk p16+ Recruiting
 TLR8 Cetuximab + SOC Chemo (CDDP + 5-FU) +/− VTX-2337 II NCT01836029 Recurrent or metastatic HNSCC Ongoing, not recruiting
 TLR8 Cetuximab + VTX-2337 window of opportunity before surgery Ib NCT02124850 Stage II-IVA resectable HNSCC Recruiting